Department of Psychiatry, Inje University College of Medicine, Goyang, Korea.
Psychiatry Investig. 2009 Mar;6(1):39-43. doi: 10.4306/pi.2009.6.1.39. Epub 2009 Mar 31.
Weight gain is a possible adverse effect of the use of antipsychotics, and is an important factor for long-term health and treatment compliance. Olanzapine is an atypical antipsychotic known to cause considerable weight gain. A relationship between weight gain and the G protein beta3 subunit gene (GNB3) 825C/T polymorphism has been reported. We therefore examined this possible association in a Korean schizophrenic patient group receiving olanzapine treatment.
Weight and height measurements were obtained prior to starting olanzapine and measured again after long-term treatment. Genotyping for the 825C/T polymorphism was performed using a PCR-based method.
We found that long-term treatment with olanzapine resulted in mean gains in weight and body mass index (BMI) of 5.2 kg and 1.93 kg/m(2), respectively. There was a no significant difference in the mean body weight change from baseline to the endpoint after olanzapine treatment between the genotype groups (p=0.796). There were also no significant differences in genotype or allele frequencies between the severe weight-gain (more than 10%) and minimal weight-gain (less than 10%) groups (chi(2)=0.037, p=0.98; chi(2)=0.020, p=0.89).
The finding from this study thus does not support a relationship between the GNB3 825C/T polymorphism and weight gain in Korean schizophrenic patients receiving olanzapine treatment.
体重增加是使用抗精神病药的一种可能的不良反应，也是长期健康和治疗依从性的重要因素。奥氮平是一种已知会导致体重明显增加的非典型抗精神病药。已经报道了体重增加与 G 蛋白β3 亚单位基因（GNB3）825C/T 多态性之间的关系。因此，我们在接受奥氮平治疗的韩国精神分裂症患者群体中检查了这种可能的关联。
在开始使用奥氮平之前和长期治疗后再次测量体重和身高。使用基于 PCR 的方法进行 825C/T 多态性的基因分型。
我们发现，长期使用奥氮平治疗导致体重和体重指数（BMI）的平均增加分别为 5.2 公斤和 1.93 公斤/平方米。奥氮平治疗后从基线到终点的平均体重变化在基因型组之间没有显著差异（p=0.796）。在严重体重增加（超过 10%）和最小体重增加（小于 10%）组之间，基因型或等位基因频率也没有显著差异（卡方=0.037，p=0.98；卡方=0.020，p=0.89）。
因此，这项研究的结果不支持 GNB3 825C/T 多态性与接受奥氮平治疗的韩国精神分裂症患者体重增加之间的关系。
